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Abstract: Fibromyalgia (FM) diagnosis follows the American College of Rheumatology (ACR) criteria,
based on clinical evaluation and written questionnaires without any objective diagnostic tool. The lack
of specific biomarkers is a tragic aspect for FM and chronic pain diseases in general. Interestingly, the
endogenous opioid system is close to the immune one because of the expression of opioid receptors
on lymphocytes membrane. Here we analyzed the role of the Mu opioid receptor on B lymphocytes
as a specific biomarker for FM and osteoarthritis (OA) patients. We enrolled three groups of females:
FM patients, OA patients (chronic pain control group) and healthy subjects (pain-free negative control
group). We collected blood samples to apply immunophenotyping analysis. Written tests were
administrated for psychological analysis. Data were statistically analyzed. Final results showed
that the percentage of Mu-positive B cells were statistically lower in FM and OA patients than in
pain-free subjects. A low expression of Mu-positive B cell was not associated with the psychological
characteristics investigated. In conclusion, here we propose the percentage of Mu-positive B cells as a
biological marker for an objective diagnosis of chronic pain suffering patients, also contributing to the
legitimacy of FM as a truly painful disease.
Keywords: chronic pain diagnosis; chronic pain biomarkers; opioid receptors; lymphocytes;
fibromyalgia; osteoarthritis
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1. Introduction
Fibromyalgia (FM) is one of the most disabling chronic pain syndromes [1] affecting especially
women and middle-aged people with a global prevalence between 0.2% and 6.6% [2–4]. In addition
to chronic pain, hallmark symptoms of FM often include chronic fatigue, sleep disturbances, cognitive
dysfunctions (the so-called “fibro-fog”) and other somatic symptoms [5].Moreover, from a psychological
viewpoint, FM is associated with distress in terms of depression, anxiety and stress-related symptoms [1,6].
Within the last International Association for the Study of Pain (IASP) meeting, FM has been included in
the International Classification of Diseases (ICD-11) inside the category of “chronic primary pain” [7].
Thus, FM is now recognized by specialists as a pathological condition, characterized by a chronic
primary pain state, which could be assimilated as a disease in its own right, as already proposed by
Raffaeli and colleagues [8]. However, FM is sometimes still considered as a psychological illness and
not a “real disease”, and FM patients are frequently labeled with the diagnoses of “somatoform pain
disorder” or “affective disorder” [9]. Thus, FM still represents a clinical enigma with real diagnostic
difficulties since its pathophysiology is not well known and its symptoms are nonspecific and overlap
with many other disorders [10].
The American College of Rheumatology (ACR) criteria for FM diagnosis have changed over
time [5,11–13], maintaining advantages and limitations [14], and clinicians rely only on clinical
examination and questionnaire administration to make a diagnosis [15]. Neither specific diagnostic
laboratory tests nor biomarkers are available to confirm FM diagnosis, especially in its specificity
of chronic widespread pain (CWP), excluding some groundbreaking tests available in the near
future [16]. In this context, delays and misdiagnosis may frequently occur, with relevant consequences
on patients’ life and treatment efficacy, as well as socioeconomic burdens on patients and the health
care system [17–21]. For these reasons, the identification of objective and specific FM biomarkers is a
priority for correct diagnosis. In this field, it has been suggested that FM cannot be diagnosed with a
single biomarker, although proteins found to be involved in FM pathogenesis could play an important
role in a specific subset of the syndrome [22,23].
Evaluation of cytokines and chemokines levels in stimulated peripheral blood mononuclear cell
(PBMC) has shown patterns uniquely present in patients with FM [24,25]. Metabolomics analysis
through the innovative technique called “vibrational spectroscopy” [16] has detected a “molecular
fingerprint” in blood samples, specific for FM patients. More recently, Niculescu and colleagues [26]
have proposed putative “risk genes”, showing a higher expression, and putative “protective/resilience
genes”, with a lower expression, in severe pain states. In recent years, attention has been focused on
the close association between peripheral nerve and opioid-containing immune cells [27]. Both immune
cells and neurons share common ligands and receptors, and this ligand-receptor communication
influences and activates cellular pathways in both systems [28]. Immune cells express a myriad of
opioid receptors: µ (Mu[MOR]/Oprm1), δ (delta [DOR]/Oprd1) and κ (kappa [KOR]/Oprk1) [29].
Human studies have demonstrated that short-term morphine induces T-lymphocytes cytokines release
from T cells, by enhancing the differentiation of B-lymphocytes [30]. Moreover, Mu agonists increase
IgM and IgG production by B cells but the ability to produce antibodies also requires the cooperation
of other immune cells, expressing opioid receptors, as well. Mu activation by morphine has also been
shown to regulate macrophage functions, including nitric oxide production and phagocytosis [31], and
macrophages Mu is up-regulated by several cytokines [32]. However, little is known about the role of
opioid receptors on circulating cells during the development of a chronic pain disease.
Since the 1990s, Raffaeli and colleagues have investigated the clinical combined role of opioids
and the immune system, in order to personalize pain therapy [33–39], by underlining that clinical
use of opioids could interact with the endogenous antinociceptive systems [40] and these interactions
are different for diverse pain pathologies [41]. The complex communication between endogenous
antinociceptive systems, pathology and peripheral opioid receptors has encouraged us to postulate a
role for the lymphocyte opioid Mu receptor as a biomarker for FM diagnosis.
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Thus, here we propose an observational, cross-sectional, single blind, diagnostic trial in order
to investigate whether Mu opioid receptor on lymphocyte membranes could be considered as a FM
biomarker or whether it could be a common marker for different chronic pain syndromes. Moreover,
given the high prevalence of psychological distress and psychiatric disorders in FM and more in general
in chronic pain [6,42,43], and the identification of different psychobiologic FM profiles [44], we also
investigate whether differences in Mu opioid receptor expression could be influenced by psychological
aspects relevant in chronic pain diseases and FM. In particular we focused on illness perception,
coping and catastrophizing, pain acceptance and depression, as well as anxiety and stress-related
symptoms [6,45–49].
2. Results
2.1. Demographic and Clinical Characteristics
Following inclusion and exclusion criteria assessment (see 4.2 paragraph), clinical data were
collected in a specific Case Report Form (CRF)including: demographics, clinical characteristics and
pharmacological history (Table 1).Pain intensity analysis was measured using the 11-point numerical
rating scale (NRS) test, where 0= No pain and 10= worst possible pain. The totality of enrolled patients
was female (n = 102), mean age 51 years (Table 1). Fifty-eight percent (58%) were fibromyalgic patients,
19% were osteoarthritic (OA) patients and the remaining 23% were pain-free people. All of the FM
patients (n = 59) ranked between moderate (NRS: (4–6); 15.3%) and severe (NRS:(7–10); 84.75%) NRS
score. Fifty-nine percent were patients suffering for less than five years, 41% for more than five years.
OA patients (n = 19) rated with mild pain (NRS: (0–3); 36.87%), moderate (26.4%) and severe pain
(36.87%); 63.1% of OA patients had pain for less than five years and the remaining 36.93% for more than
five years (Table 2). All patients were following a personal pharmacological therapy prior to enrollment:
41% antidepressants; 14% benzodiazepines; 5% non-steroidal anti-inflammatory drugs (NSAIDs); 19%
a combination of the previous drugs; 21% nutritional supplement or nothing. All of the enrolled FM
and OA patients undergoing biological investigation received psychological questionnaires and 63 of
them (FM patients n = 53, OA patients n = 10) filled them.
Table 1. Clinical characteristics: patients and healthy subjects were analyzed considering the diagnosis,
the intensity of pain (11-point numerical rating scale (NRS)) and the duration of pain (years).
ClinicalCharacteristics % Of Patients (n=102)
Diagnosis
Fibromyalgia (FM) 57.8 (n = 59)
Musculoskeletaldisorders (OA) 18.6 (n = 19)
Healthypeople 23.5 (n = 24)
Intensity of Pain (NRS) FM OA
(1–3) MildPain (n = 0) 42.1 (n = 8)
(4–6) Moderate Pain 15.3 (n = 9) 26.4 (n = 5)
(7–10) Severe Pain 84.7 (n = 50) 31.5 (n = 6)
None
Duration of Pain FM OA
<5 years 59.3 (n = 35) 63.1 (n = 12)
>5 years 40.7 (n = 24) 36.9 (n = 7)
2.2. Biological Results
2.2.1. Mu Opioid Receptors on T and B Lymphocytes Membrane
We analyzed the blood samples of all enrolled patients in order to detect the expression of Mu
receptors on the membrane of T and B lymphocytes. We used one-way Analysis of Variance (ANOVA)
both for group comparisons and for intra-group homogeneity assessment. All data were expressed as
mean ±S.E.M. Tukey’s least significant difference multiple comparison was used for post-hoc analysis
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following one-way ANOVA, to compute the probability values (P) in three-group comparison. A P
threshold of 0.05 was considered for statistical significance.
We found that only a very low (mean < 1.3 ± 0.3) percentage of T lymphocytes from FM and OA
patients and CTRL expressed Mu opioid receptor (Figure 1B), and we did not find any significant
difference of expression for the Mu receptor between groups. Interestingly, a consistent percentage of
B lymphocytes of FM, OA and negative control group patients expressed MOR: we found intra-group
homogeneity (FM mean: 18.2 ± 1.7; OA mean: 30.96 ± 5.5; CTRL(−) mean: 43.80 ± 3.5) and significant
differences of Mu expression between CTRL and FM (p < 0.001), and CTRL and OA ( p< 0.05)
(Figure 1D).
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Figure 1. Flow cytometry analysis of the Mu opioid receptor in fibromyalgia (FM), osteoarthritis (OA)
and CTRL(−) patients in T lymphocytes (A) and B lymphocytes(C). Mu+ T cells percentage (B) and
Mu+ B cells percentage (D) in FM, OA, CTRL(−) patient groups.
2.2.2. Correlation between Intensity of Pain (NRS Scale) and Mu-Positive B Cells
Both FM and OA patients are characterized by pain. Considering that not all of the patients felt
pain the same way, we wanted to investigate whether such differences could depend on opioid receptor
expression on circulating cells. Thus, we compared MOR expression on B lymphocytes, by focusing
on the intensity of pain betwee FM and OA patients versus the pain-free egative control group.
FM patients, ranking between moderate (NRS (4–6)) and severe (NRS (7–10)) pain, did not present
any differences in the percentage of Mu-positive (Mu+) B cellsbut both of the subgroups showed a
significantly (p < 0.001) lower expression of Mu+ B cells (respectively, mean: 20.98 ± 3.5; 18.82 ± 2.0)
t an the control group (mean: 43.80 ± 3.5) (Figure 2A). OA patients declaring moderate pain (NRS
(4–6)) (mean: 13.22 ± 4.2) and severe pain (NRS (7–10)) (mean: 23.25 ± 5.6) showed insignificant
differences; mild pain OA patients (NRS (1–3)) presented a significantly higher percentage of Mu+ B
cells (mean: 52.77 ± 9.2) but not significantly different from Mu expression of control group patients
(mean: 43.80 ± 3.5) (Figure 2B).
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Considering that moderate and sev re pain FM and OA patients did not show any significant
differe ces in Mu+ B cell expression, we assembled the subgroups together in order to compare
Mu expression in patie ts with different pathologies but the same intensity of pain, versu the
negative control group. We found that moderate/severe ai : 19.19 ± 1.8) and
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and the mild pain group patients (mean: 52.77 ± 9.2). These last groups did not show any significant
differences in the percentage of Mu+ B lymphocytes (Figure 3).
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2.2.3. Correlation between Duration of Pain and Mu Positive B Cells
We analyzed the percentage of expression of Mu+ B cells in both of the FM and OA subgroups
versus the control group, by considering the number of years after pain insurgence. Fifty-six percent
(56%) of FM patients (n = 33) were suffering for more than five years; the remainder were suffering
for less than five years (54%, n = 26). We found a significant difference (p < 0.001) of percentages of
Mu+ B cells between the two subgroups (respectively, mean: 23.80 ± 2.1; 11.50 ± 1.9) and between the
single subgroups and the control pain-free group (mean: 43.80 ± 3.5) (Figure 4A). Sixty-three percent
(63%) of OA patients (n = 12) were suffering for less than five years, and 37% (n=7) for more than
five years. The percentage of Mu+ B cells was not significantly different between the two subgroups
(respectively, mean: 39.67 ± 8.2; 25.88 ± 7.2). We found a significant difference (p < 0.05) in Mu+ B
expression between the control group and OA patients suffering for less than five years (Figure 4B).
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Figure 4. (A)FM patients suffering for more than 5 years showed a significantly higher percentage of
Mu+ B cells than patients suffering for less than 5 years; the negative control group expressed a Mu+ B
cells percentage that was significantly higher than both of the two FM subgroups. (B) OA patients
suffering for less than 5 years showed a significantly lower percentage of Mu+ B lymphocytes than the
negative control group.
2.2.4. Correlation between Drugs Therapy before Enrollment and Mu-Positive BCells
Both fibromyalgic and osteoarthritic patients require pharmacological therapies in order to alleviate
their pain. In most cases, medical doctors also decide on a combination of drugs and prescribe
formulations for psychological and psychiatric comorbidities, for FM patients. OA patients mostly used
NSAIDs for inflammatory pain. Considering the pharmacological therapy at the time of enrolment,
we analyzed whether Mu opioid receptor expression on B lymphocytes was influenced by the therapy.
We considered the totality of patients and divided the entire number into the following therapy
subgroups: antidepressants, benzodiazepines, NSAIDs, nutritional supplement/none, and previous
drugs combination. We found that, despite the different pharmacological therapies, the percentage of
Mu+ B cells was almost identical across the subgroups (mean: 18.3):antidepressant 17%; benzodiazepines
20%; NSAIDs 22%; nutritional supplements/none 21%; previous drugs combination 20%.
2.3. Correlations between Mu-Positive B Cells and Psychological Variables
Table 2 shows correlation coefficients among Mu+ B cells percentages and psychological variables
in FM patients (n = 53). Mu+ B cell expression had no significant correlations with any psychological
aspects investigated.
Int. J. Mol. Sci. 2020, 21, 1499 7 of 15
Table 2. Mu+ B cells percentage of expression had no significant correlations with any psychological
aspects investigated. Pearson’s correlations between Mu+ B cells percentage of expression and total
FIQ score, IPQ-R subscales, CSQ subscales, total CPAQ score and DASS subscales.
Mu+ B Cells % of Expression
FIQ −0.39
IPQ-R—Timeline acute/chronic −0.101
IPQ-R—Timeline cyclical −0.062
IPQ-R—Consequences −0.093
IPQ-R—Personal control 0.056
IPQ-R—Treatment control 0.089
IPQ-R—Illnesscoherence 0.046
IPQ-R—Emotional representation 0.090
CSQ—Distraction 0.135
CSQ—Catastrophizing −0.012
CSQ—Ignoring pain sensations 0.057
CSQ—Distancing from pain 0.107
CSQ—Coping self-statements 0.028
CSQ—Praying −0.032
CPAQ −0.021
DASS—Depression 0.064
DASS—Anxiety 0.053
DASS—Stress 0.105
Values are Pearson’s correlation coefficients.* p < 0.05; ** p < 0.01. FIQ = Fibromyalgia Impact Questionnaire; CSQ =
Coping Strategies Questionnaire; CPAQ = Chronic Pain Acceptance Questionnaire; DASS-21 = Depression, Anxiety
and Stress Scale.
Given the similarities in Mu+ B cells percentages between FM and OA patients at the same
intensity of pain (NRS (4–6), NRS (7–10)), we conducted the analysis considering together FM and OA
patients with moderate and severe pain (n = 58). Table 3 Shows correlation coefficients among Mu+ B
cells percentage and psychological variables. Mu+ B cells expression had no significant correlations
with any psychological aspects investigated.
Table 3. Mu+ B cells percentage of expression had no significant correlations with any psychological
aspects investigated. Pearson’s correlations between Mu+ B cells percentage of expression and total
FIQ score, IPQ-R subscales, CSQ subscales, the total CPAQ score and DASS) subscales.
Mu+ B Cells % of Expression
FIQ/OA-FIQ-R −0.027
IPQ-R—Timeline acute/chronic −0.241
IPQ-R—Timeline cyclical −0.067
IPQ-R—Consequences −0.155
IPQ-R—Personal control 0.022
IPQ-R—Treatment control 0.122
IPQ-R—Illness coherence 0.006
IPQ-R—Emotional representation 0.133
CSQ—Distraction 0.055
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Table 3. Cont.
Mu+ B Cells % of Expression
CSQ—Catastrophizing −0.014
CSQ—Ignoring pain sensations −0.043
CSQ—Distancing from pain 0.036
CSQ—Coping self-statements 0.065
CSQ—Praying 0.024
CPAQ 0.031
DASS—Depression −0.015
DASS—Anxiety 0.074
DASS—Stress 0.105
Values are Pearson’s correlation coefficients. * p < 0.05; ** p < 0.01. FIQ = Fibromyalgia Impact Questionnaire;
OA-FIQ-R= Osteoarthritis- FIQ Revised; IPQ-R = Illness Perception Questionnaire-Revised; CSQ = Coping Strategies
Questionnaire; CPAQ = Chronic Pain Acceptance Questionnaire; DASS-21 = Depression, Anxiety and Stress Scale.
3. Discussion
Chronic pain diagnosis lacks specific tools to objectively define pathology, unlike other diseases
(e.g., oncology or infectiology), where biomarkers play a well-known role.
In this context, the objective evaluation of pain intensity is a crucial point, relevant for
pharmacological management and especially for the choice of opioid therapy or to determine if
or not to use a surgical approach (e.g., prosthesis implantation or neurostimulation). Thus, the proper
diagnosis of pain severity has also an ethical and economical value, in terms of social and national
health system costs.
The objectivity of pain severity is still described only in terms of pain threshold and patients have
to rate their pain considering a numeric rating scale (NRS) of 0 to 10, where zero is a no pain condition
and a 10 means the pain is as bad as it could be [50], even if it involves many other factors, such as
anthropological, spiritual, genetic, social, and psychological personal experiences [51].
There is no internationally accepted classification of pain severity for FM or chronic diseases and
the physician is tasked with careful evaluation in order to determine the most effective treatment [15].
It is often suggested that a distinction has to be made between mild, moderate and severe forms of FM,
based on symptom intensity and functional disability [52].
Although FM has been included in the ICD-11 as “chronic primary pain” [7], a great number of
clinicians still consider it as a somatoform pain disorder and FM diagnosis is based principally on the
main symptom of widespread pain. As with other chronic pain syndromes, FM is characterized by
non-specific and overlapping symptoms.
The absence of objective diagnostic tools is leading scientists to the identification of chronic pain
markers, in order to improve the diagnostic process and reduce the risks of diagnostic delays and
misdiagnosis [53,54]. An objective diagnosis could allow a better classification of these chronic diseases,
by clarifying pathogenetic mechanism, prognosis and/or response to treatment, opening the way to
personalized medicine. The importance of biomarkers to guide chronic pain diagnosis and treatment
properly assumes an even greater impact, considering the lack of valid molecular markers for diagnosis
for all the chronic pain states [53,55].
In this context, in recent years we have focused on the expression of the Mu opioid receptor on
lymphocyte membrane, in order to identify this receptor as a hypothetical biomarker of chronic pain
conditions. Focusing on the evidence that immune, nervous and opioid endogenous systems share the
same opioid receptors, in the 1990sRaffaeli and colleagues studied and reported their crucial role in the
pain pathways [56] and published a trial based on this idea related to osteoarthritic chronic pain in
patients who underwent hip surgery [54].
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In the present study, we certified that FM pain perception is an objective widespread chronic
pain status where pain is the primary symptom and FM pathogenesis derives from a characteristic
morphological modulation of the endogenous antinociceptive pathway. To demonstrate this, we chose
OA as a chronic pain control group, considering our previous research on osteoarthritic pain [54] and
its well-described nociceptive pain due to degenerative osteoarthritis status [57,58], and compared
immunophenotype analysis of FM and OA patients with a pain-free negative control group.
We found that both FM and OA chronic pain patients present a diverse and significantly lower
percentage of Mu+ B cells compared to the negative control group.
In our experiments, Mu receptor in T cells was expressed only by a very low frequency population
(less than 2%) and there was no difference between the percentage of Mu+ T cells across the three
groups, suggesting that the frequency of Mu+ T cells expression could not be a significant biological
target in chronic pain patients. However, further investigation will be required to better understand
this intriguing data.
Thus, we analyzed these data considering the intensity of the pain and found, for the first time, that
FM or OA patients with moderate/severe intensity of pain on the NRS presented a lower percentage of
B cells expressing Mu opioid receptor than patients in pain-free control group. Of interest is the finding
that OA patients with a mild pain sensation showed a higher percentage of Mu+ B lymphocytes, which
was not significantly different from the negative control group.
The analysis of these data led us to postulate that FM patients effectively show a real pain condition,
by having an overlapping opioid marker of the well-established OA patient pain, and their suffering is
not merely psychosomatic expression.
As a clinical explanation for our results, we suggested that a lower expression of Mu+ B cells in
FM and OA patients than in the negative control group seems to be linked to a reduced threshold
level of pain response and that a low availability of opioid receptors in FM patients could show
altered endogenous opioid analgesic activity. Similar results were presented about Mu opioid receptor
accessibility in the central nervous system of FM patients, where a reduction was detected [59]. Thus,
a scarce Mu opioid reserve could be an indicator of low cooperation of the endogenous opioid system
in the prevention of chronic pain development. Understanding the role of Mu on lymphocytes
could be helpful in the management of chronic pain-suffering patients undergoing rehabilitation
programs. In the near future, it could be relevant to verify our findingin acute pain conditions and in
inflammatory-related disease.
Raffaeli and coworkers here propose that this condition could be classified as the “B-Lymphocytic
Reserve MOR Syndrome” theory. Even if further studies are needed in this direction, we postulate
that during an endogenous or exogenous pain stimulus, the amount of B lymphocytes presenting
MOR could contribute to counteract the algic response. Unlikely, when the intensity of pain appears
more severe (high/moderate intensity) we assist to the reduction of Mu+ B cells percentage, and this
deficit of B cells presenting MOR could affect pain perception and intensity, leading to an uncontrolled
pain condition. Further studies are already ongoing to better identify the possible correlation of the
different activation statuses of B lymphocytes with Mu+ Bcells frequency. In this study, we also found
two different subpopulations of FM patients considering the duration of pain in years: here we show
that FM patients suffering for more than five years have a lower percentage of Mu+ B cells than a
subgroup of FM patients suffering for less than five years. In the near future, it could be interesting
to analyze the modulation of the percentage of Mu+ B cells expression over the time, by following a
specific group of patients from the first clinical evidence of FM.
Moreover, we found that the expression of Mu+ B cells is not associated with functional disability,
illness representation, depression, anxiety, stress-related symptoms, coping, catastrophizing or pain
acceptance. Therefore, these relevant psychological aspects do not seem to correlate with the biological
findings, as shown in Tables 2 and 3.
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In conclusion, our results could contribute to the legitimization of FM as a real and serious chronic
pain syndrome and could also be helpful in rethinking the description of pain categories: FM and OA
are differently categorized in the ICD-11 but our results show similar biological characteristics.
Due to this new evidence and to better depict the chronic pain scenario, new trials have already
been submitted to the ethical committee in order to clarify whether the “B-Lymphocytic Reserve MOR
Syndrome” hence the modulation of B cell presenting MOR is common to more than one chronic pain
condition. Further investigation could help clinicians understand if these pathologies share the same
pattern of pain.
4. Materials and Methods
4.1. Trial Design
This is an observational, cross-sectional, single blind, diagnostic trial. The current study is
approved by the institutional independent ethics committee of Sapienza University of Rome, with
the name of “I markers Bio-Psico-Sociali nella syndrome fibromialgica” (Fibromyalgia syndrome
Bio-Psycho-Social markers), on 8 March 2018 (Ref. 4937) and the trial is registered in on ISRCTN
registry, ID: ISRCTN24645566, 10 December 2018.
4.2. Participants
All participants were enrolled at the Clinic for the Diagnosis and Therapy of Fibromyalgia,
Rheumatology Unit, Sapienza University of Rome (Umberto I Policlinic).
Fifty-nine (59) consecutive adult patients affected by FM, according to both 1990 and 2010 ACR
criteria [1,2], were enrolled. Inclusion criteria allowed the eligibility of adult (18–65 years old) FM
patients, both males and females.
Considering that opioid receptors and lymphocytes activity could be influenced by opioid
treatment [19–35], patients currently being treated with opioids were not enrolled. However, information
about the assumption of pharmacological therapy was collected. Exclusion criteria involve also patients
with rheumatic pathologies.
A control group of 19OA patients (chronic pain control group) affected by chronic pain due to
knee or hip degenerative osteopathy, ongoing active and/or passive therapy, paracetamol and NAISDs
for mild/severe pain when needed, was involved.
A second control group was composed by 24 healthy people (pain-free negative control group).
All eligible and consenting patients signed a specific informed consent form and General Data
Protection Regulation (GDPR) obligations, on the day of the first clinical visit. Each allocated patient,
after inclusion/exclusion criteria analysis, clinical evaluation and consent form signature were included
in a list, with a numeric sequential code, in order to protect confidentiality. Only the medical doctor
could access patient names. All information was collected in electronic files.
4.3. Clinical and Psychological Measurements
Clinical evaluation and socio-demographic characteristics were assessed by clinicians operating
in Sapienza University.
Clinical data were collected during patients’ enrolment. Clinicians filled the database following a
consequential numbering of the patients.
All patients and pain-free people underwent clinical examination. Questions were included about
socio-demographic characteristics, duration of pain, comorbidities and current treatments. Clinical
pain was reported on a 0–10 Numerical Rating Scale (NRS), with 0 for “no pain” and 10 for “the worst
pain imaginable.”
A comprehensive battery of self-report tools in their Italian versions was administered to the
patients of experimental and positive control groups. The Fibromyalgia Impact Questionnaire (FIQ; [60])
was administered in order to assess functional disability. The FIQ is a 10-item self-administered
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instrument that measures physical functioning, work status, depression, anxiety, sleep, pain, stiffness,
fatigue and well-being. Higher scores indicate greater functional disability. In our study, the
original FIQ was adapted in OA sample changing the terminology “fibromyalgia” into “osteoarthritis”
(Osteoarthritis-FIQ Revised: OA-FIQ-R).
The Illness Perception Questionnaire-Revised (IPQ-R; [61]) is a 38-itemmeasure of illness
representation in terms of perceived duration, consequences, understanding, control, and emotional
impact of illness. Coping Strategies Questionnaire (CSQ; [62]) is a 27-itemmeasure of coping strategies
used by patients to manage chronic pain, such as catastrophizing, distraction, denial, distancing,
self-affirmation, and praying. Depression, Anxiety and Stress Scale-21 (DASS-21; [63]) is a 21-items
measure of psychological distress in terms of anxiety, depressive and stress-related symptoms. Chronic
Pain Acceptance Questionnaire (CPAQ; [64]) is a 20-itemmeasure of pain acceptance based on persistence
in doing pleasant activities instead of trying to control pain and avoid activities.
4.4. Blood Assays
Blood samples were collected during clinical examination. Blood samples were analyzed within
the next 24 h through immunophenotyping analysis. The research biologists were blinded to patients’
personal information and therapy. They received patients’ samples in a sequential numeric code.
4.5. Biological Analysis
Immunophenotyping Analysis
Peripheral blood was incubated with fluorochrome-conjugated antibodies, specific for different cell
population membrane markers, in combination with Mu anti-opioid receptor antibody. In particular,
peripheral blood samples were stained with antibodies FITC conjugated anti CD3 (T lymphocytes),
APC conjugated anti-Mu and PerCP-Cy5.5 conjugated anti-CD19 (B lymphocytes), all from Becton
Dickinson, for 20 min at 4 ◦C. After staining, samples were incubated for 15 min at room temperature
with BD FACS Lysing Solution (Becton Dickinson, Milano, Italy) and then centrifuged at 1500 RPM
for five minutes. The resulting pellets were acquired immediately after adding PBS. Acquisition
and analysis were performed on a LSR Fortessa X-20 flow cytometer (Becton Dickinson) using Diva
software, in order to detect the percentage of Mu+ cells.
4.6. Statistical Analysis
Immunophenotyping results were analyzed by one-way ANOVA test for group comparisons and
for intra-group homogeneity assessment, with Prism-GraphPad 8.0.2 software (San Diego, CA, USA).
All data were expressed as mean ± S.E.M. Tukey’s least significant difference multiple comparison
was used for post-hoc analysis following one-way ANOVA, to compute the probability values (P) in
three-group comparison. A P threshold of 0.05 was considered statistically significant.
Descriptive statistics were used to describe socio-demographic data, diagnosis, pain intensity and
pain duration.
Statistical analysis of psychological data was performed with SPSS 23 software. The Pearson’s
parametric coefficient was used for the correlation analysis.
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